Heidemarie Dobias

Heidemarie Dobias is a Researcher at the University Institute of Physiology and Pathophysiology, Paracelsus Medical University Salzburg. Her work focuses on cancer biology, ferroptosis mechanisms, and hepatobiliary system pathophysiology. She has led research projects on anti-cancer drug development and endocannabinoid system roles in cartilage repair. Dr. Dobias collaborates on teaching modules such as 'Molecular Cell Biology for Pharmacists' and 'PhysPath Pharmacy Practicum'. She has published over 24 articles since 2010, with recent emphasis on biliary tract cancer treatments and radon therapy outcomes in musculoskeletal conditions.

Research Interests: Ferroptosis regulation in cancer cells, drug development for biliary tract tumors, epigenetic therapies in oncology, and complementary medicine applications. Her work bridges molecular pharmacology with clinical outcomes in chronic diseases.

Projects:

• Establishing ouabain as an anti-cancer drug (2018–2019)
• Endocannabinoid system’s role in cartilage repair (2016–2017)

Grants & Funding: Multiple institutional grants supporting her research on ferroptosis, radon therapy, and drug efficacy studies.

Labs/Teams: Active in the Physiology and Pathophysiology research group at PMU Salzburg, collaborating with interdisciplinary teams in oncology and rheumatology.